周五盘前，医疗器械公司Globus Medical（股票代码：GMED）股价大幅上涨31.10%，引发市场广泛关注。这一显著涨幅主要源于公司发布强劲的第三季度财报以及多家知名券商上调对该公司的评级和目标价。
根据公司公布的财报，Globus Medical第三季度销售额达7.69亿美元，超过分析师预期的7.3435亿美元；每股收益为1.18美元，同样大幅超过市场预期的0.78美元。公司首席执行官Keith Pfeil表示，第三季度收入同比增长23%，主要得益于美国脊柱业务10%的增长，以及公司产品和地区的广泛需求加速了发展势头。
多家知名券商随即上调了对Globus Medical的评级和目标价。杰富瑞证券将目标价从88美元大幅上调至105美元，上调幅度达到19.3%。加拿大皇家银行也将其目标价从88美元提高到92美元。更值得注意的是，Truist Securities将Globus Medical的评级从"持有"上调至"买入"，并将目标价从65美元大幅上调至93美元，上调幅度高达43%。这些积极的分析师评级变化表明，华尔街对公司未来的业务前景和增长潜力持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.